Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 26:15:1-8.
doi: 10.15420/ecr.2019.10. eCollection 2020 Feb.

Antithrombotic Therapy After Transcatheter Aortic Valve Implantation

Leslie Marisol Lugo  1 , Rafael Romaguera  2 , Joan Antoni Gómez-Hospital  3 , José Luis Ferreiro  3
Affiliations
Review

Antithrombotic Therapy After Transcatheter Aortic Valve Implantation

Leslie Marisol Lugo et al. Eur Cardiol. .

Abstract

The development of transcatheter aortic valve implantation has represented one of the greatest advances in the cardiology field in recent years and has changed clinical practice for patients with aortic stenosis. Despite the continuous improvement in operators' experience and techniques, and the development of new generation devices, thromboembolic and bleeding complications after transcatheter aortic valve implantation remain frequent, and are a major concern due to their negative impact on prognosis in this vulnerable population. In addition, the optimal antithrombotic regimen in this scenario is not known, and current recommendations are mostly empirical and not evidence based. The present review aims to provide an overview of the current status of knowledge, including relevant on-going randomised trials, on antithrombotic treatment strategies after transcatheter aortic valve implantation.

Keywords: Antithrombotic therapy; anticoagulant therapy; antiplatelet therapy; aortic stenosis; transcatheter aortic valve implantation; transcatheter aortic valve replacement.

PubMed Disclaimer

Conflict of interest statement

Disclosure: JLF has received honoraria for lectures from Eli Lilly, Daiichi Sankyo, AstraZeneca, Roche Diagnostics, Pfizer, Abbott, Boehringer Ingelheim and Bristol-Myers Squibb; consulting fees from AstraZeneca, Eli Lilly, Ferrer, Boston Scientific and Pfizer; and research grants from AstraZeneca. LML has received a grant from the National Council on Science and Technology, Mexico (CONACYT). All other authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Potential Complications and Putative Benefits and Limitations of Antithrombotic Strategies in Transcatheter Aortic Valve Implantation Patients
Figure 2:
Figure 2:. Outcomes of Randomised Clinical Trials Comparing Dual Versus Single Antiplatelet Therapy with Aspirin After Transcatheter Aortic Valve Implantation
Figure 3:
Figure 3:. On-going Randomised Trials Evaluating Antithrombotic Strategies After Transcatheter Aortic Valve Implantation
See this image and copyright information in PMC

References

    1. Baumgartner H, Falk V, Bax JJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91. doi: 10.1093/eurheartj/ehx391. - DOI - PubMed
    1. Nishimura RA, Otto CM, Bonow RO et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89. doi: 10.1016/j.jacc.2017.03.011. - DOI - PubMed
    1. Leon MB, Smith CR, Mack MJ et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20. doi: 10.1056/NEJMoa1514616. - DOI - PubMed
    1. Reardon MJ, Van Mieghem NM, Popma JJ et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–31. doi: 10.1056/NEJMoa1700456. - DOI - PubMed
    1. Mack MJ, Leon MB, Thourani VH et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695–705. doi: 10.1056/NEJMoa1814052. - DOI - PubMed